No abstract

5% of all ovarian tumours are accounted to germ cell tumours (GCT’s). Affecting mostly young women, the highest incidence is seen in second and third decade of life. They are highly malignant but chemosensitive and more curable than their epithelial counterparts. Treating these tumors with effective surgery and combination chemotherapy survival rates have dramatically improved in recent decades.  We present our experience of ovarian germ cell tumours in theDepartment of Surgical Oncology, Rajendra Institute of Medical Sciences (RIMS), Ranchi with special emphasis on treatment outcomes. A retrospective review of hospital medical records of patients with ovarian germ cell tumours diagnosed and treated at RIMS from June 2019 to August 2020, was performed. Clinical profile and treatment outcome of patients were recorded. A total of 19 patients met criteria. The median age at diagnosis was 20 years (range 11–42 years) and all had good performance status. All except two patients underwent surgery, 70.6% and 29.4% in upfront and interval debulking surgery (IDS) setting respectively.  Fertility preserving surgery was done in 75% patients in the primary surgery group and 60% undergoing IDS.  83.3% patients received BEP as adjuvant chemotherapy whereas 80% as neo-adjuvant chemotherapy. Majority (31.5%) patients had dysgerminoma as final histology, followed by mixed histology(26.3%), yolk sac tumour (15.7%), immature teratoma (15.7%) and choriocarcinoma (10.5%) 47.3% patients were in Stage I at the time of diagnosis. 78.9%  patients were alive without disease, 10.5% recurred,  and 10.5% were lost to follow up.

No abstract

No abstract